Assessment of favorable (F) versus unfavorable (U) early stage Hodgkin's disease (HD); the Stanford V plus radiotherapy (RT) experience.

被引：1
|
作者：
Advani, R
Maeda, L
Hoppe, RT
Breslin, S
Rosenberg, SA
Baer, D
Mason, J
Horning, SJ
机构：
[1] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[2] No Calif Kaiser Permanente, Oakland, CA USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
10.1182/blood.V106.11.1932.1932
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1932
引用
收藏
页码：548A / 548A
页数：1
相关论文
共 50 条
  • [1] Stanford V and radiotherapy for advanced and locally extensive Hodgkin's disease (HD): The memorial Sloan-Kettering Cancer Center (MSKCQ) experience.
    Yahalom, J
    Edwards-Bennet, S
    Jacobs, J
    Moskowitz, CH
    Wu, EJ
    Cotler, M
    Horwitz, SM
    Noy, A
    O'Connor, OA
    Portlock, CS
    Straus, DJ
    Zelenetz, AD
    BLOOD, 2003, 102 (11) : 402A - 402A
  • [2] Stage I/II Hodgkin's disease (HD) with bulky mediastinal disease or other risk factors (RF) the Stanford V experience
    Advani, R. H.
    Hoppe, R. T.
    Rosenberg, S. A.
    Horning, S. J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 27 - 27
  • [3] Very brief (8 week) chemotherapy (CT) and low dose (30 Gy) radiotherapy (RT) for limited stage Hodgkin's disease (HD): Preliminary results of the Stanford-Kaiser G4 study of Stanford V plus RT.
    Horning, SJ
    Hoppe, RT
    Breslin, S
    Baer, DM
    Mason, J
    Rosenberg, SA
    BLOOD, 1999, 94 (10) : 387A - 387A
  • [4] Early stage Hodgkin's disease (HD) - Defining the role of radiation therapy (RT)
    Hoppe, R. T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 16 - 16
  • [5] Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease
    Aversa, SML
    Salvagno, L
    Sorarù, M
    Mazzarotto, R
    Boso, C
    Gaion, F
    Chiarion-Sileni, V
    De Franchis, G
    Favaretto, AG
    Crivellari, G
    Banna, GL
    Sotti, G
    Monfardini, S
    ACTA HAEMATOLOGICA, 2004, 112 (03) : 141 - 147
  • [6] A stage-modulated low toxic chemotherapy (VEBEP) plus low-dose radiotherapy (RT) for all stage Hodgkin's disease (HD)
    Ripa, C
    Balzarotti, M
    Siracusano, L
    Nozza, A
    Magagnoli, M
    Bertuzzi, A
    Castagna, I
    Morenghi, E
    Roncalli, M
    Santoro, A
    ANNALS OF ONCOLOGY, 2000, 11 : 55 - 55
  • [7] 12-WEEKS OF CHEMOTHERAPY AND INVOLVED FIELD RADIOTHERAPY (RT) ARE HIGHLY EFFECTIVE FOR UNFAVORABLE HODGKINS-DISEASE (HD) - THE STANFORD V REGIMEN
    BARLETT, NL
    ROSENBERG, SA
    HOPPE, RT
    HORNING, SJ
    BLOOD, 1993, 82 (10) : A333 - A333
  • [8] RADIOTHERAPY (RT) PLUS CHEMOTHERAPY (CT) VERSUS RT ALONE IN EARLY STAGE HODGKINS-DISEASE (HD), A REPORT FROM A RANDOMIZED, NATIONAL DANISH TRIAL
    NISSEN, NI
    NORDENTOFT, A
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 286 - 286
  • [9] 12 weeks of chemotherapy (stanford V) and involved field radiotherapy (RT) are highly effective for bulky and advanced stage Hodgkin's disease (HD): A limited institution ecog pilot study.
    Horning, SJ
    Bennett, JM
    Bartlett, NL
    Williams, J
    Neuberg, D
    Cassileth, PA
    BLOOD, 1996, 88 (10) : 2681 - 2681
  • [10] CEBOPP/VIML followed by radiotherapy for unfavorable early-stage or advanced-stage Hodgkin's disease.
    Nowrousian, MR
    Ernst, S
    Beling, C
    Fink, H
    Welt, A
    Schuette, J
    Moritz, T
    Flasshove, M
    Bojko, P
    Seeber, S
    Metz, KA
    Stuschke, M
    BLOOD, 2001, 98 (11) : 131A - 131A
12345